Press Releases Teva Pharmaceutical Industries Limited

Equities

TEVA

US8816242098

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
13.81 ^USD	+4.23%		+7.39%	+32.28%

Apr. 22	Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court	MT
Apr. 19	Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets	Apr. 17	AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	Apr. 16	BU
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)	Apr. 16	AQ
Teva Pharmaceutical Industries : Immediate Report	Apr. 16	PU
Teva Pharmaceutical Industries : Immediate Report	Apr. 16	PU
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets	Apr. 16	BU
Teva enters into oncology biosimilar licensing agreement	Apr. 16	AQ
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China	Apr. 11	BU
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024	Apr. 09	BU
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY Extended-Release Injectable Suspension at SIRS 2024	Apr. 08	AQ
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024	Apr. 06	BU
TEVA Successfully Opposed Trademark AZILIDE	Apr. 05	AQ
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate	Apr. 04	BU
Clinical Collaboration Agreement Established between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler Respiratory Program	Apr. 02	AQ
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement	Apr. 01	BU
TEVA UK AND CLOSED LOOP MEDICINE ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE DEVELOPMENT OF PERSONALISED MEDICINES	Mar. 27	AQ
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in China	Feb. 27	AQ
Alvotech and Teva Announce U.S. Approval of SIMLANDI injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira	Feb. 26	AQ
Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China	Feb. 26	BU
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®	Feb. 23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT